Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Dimethyl itaconate, an itaconate derivative, exhibits immunomodulatory effects on neuroinflammation in experimental autoimmune encephalomyelitis

Fig. 2

DMI alleviates BBB disruption. C57BL/6 EAE animals were administered i.p. with vehicle or DMI (400 mg/kg) every day starting from day 3 post-immunization. At day 12 post-immunization, vehicle- and DMI-treated EAE mice (n = 9/group) were subjected to i.v. administration of Evans blue. a EAE mice were sacrificed at 2 h post-Evans blue administration. The brain and spinal cord of vehicle- and DMI-treated EAE mice were harvested to assess the leakage of Evans blue. The four representative images of the brain and spinal cord harvested from vehicle- and DMI-treated EAE mice are shown. b The amount of Evans blue in the spinal cord tissues was measured and quantified. Statistical significance was determined as ***p < 0.001 by unpaired t test. c The correlation between Evans blue leakage and disease score was determined by linear regression analysis. d The spinal cord tissues harvested from vehicle- and DMI-treated EAE mice (n = 5/group) were homogenized and subjected to western blot analysis of MMP3 and MMP9 expression followed by quantification. Statistical significance was determined as *p < 0.05 and **p < 0.01 by Mann-Whitney U test

Back to article page